p53 as a target for improved cancer therapy

Bibliography

• Trends in Cancer Incidence and Mortality Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H (Eds.), IARC Scientific Publications No. 121, Lyon, France (1993).
   Google Scholar
• HUSSAIN SP, HARRIS CC: Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. (1998) 58:4023–4037.
   PubMed Web of Science ®Google Scholar
• KO LJ, PRIVES C: p53: puzzle and paradigm. Genes Dev. (1996) 10:1054–1072.
   PubMed Web of Science ®Google Scholar
• LEVINE AJ: p53, the cellular gatekeeper for growth and division. Cell (1997) 88:323–331.
   PubMed Web of Science ®Google Scholar
• SHERR CJ: Tumor surveillance via the ARF-p53 pathway. Genes Dev. (1998) 12:2984–2991.
   PubMed Web of Science ®Google Scholar
• LOWE SW, BODIS S, McCLATCHEY A et al.: p53 status and the efficacy of cancer therapy in vivo. Science (1994) 266:807–810.
   PubMed Web of Science ®Google Scholar
• CAELLES C, HELMBERG A, KARIN M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature (1994) 370:220–223.
   PubMed Web of Science ®Google Scholar
• WAGNER AJ, KOKONTIS JM, HAY N: Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p2lwafl/cipl. Genes Dev. (1994) 8:2817–2830.
   PubMed Web of Science ®Google Scholar
• HAUPT Y, ROWAN S, SHAULIAN E, VOUSDEN KH, ORENM: Induction of apoptosis in HeLa cells by transactivation-deficient p53. Genes Dev. (1995) 9:2170–2183.
   PubMed Web of Science ®Google Scholar
• BENNETT M, MACDONALD K, CHAN S, LUZIO JP, SIMARIR, WEISSBERG P: Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science (1998) 282:290–293.
   PubMed Web of Science ®Google Scholar
• CHO Y, GORINA S, JEFFREY PD, PAVLETICH NP: Crystalstructure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 265:346–355.
   PubMed Web of Science ®Google Scholar
• BÉROUD C, SOUSSI T: p53 gene mutation: software anddatabase. Nucl. Acids Res. (1998) 26:200–204.
   PubMedGoogle Scholar
• HUANG HJS, YEE JK, SHEW JY et al.: Suppression of theneoplastic phenotype by replacement of the RB gene in human cancer cells. Science (1988) 242:1563–1566.
   PubMed Web of Science ®Google Scholar
• BAKER SJ, MARKOWITZ S, FEARON ER, WILLSON JKV, VOGELSTEIN B: Suppression of human colorectal carcinoma growth by wild-type p53. Science (1990) 249:912–915.
   PubMed Web of Science ®Google Scholar
• ROTH JA, NGUYEN D, LAWRENCE DD et al.: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. (1996) 2:985–991.
   PubMed Web of Science ®Google Scholar
• ••The first published study of the use of wild-type p .5 .3 genetransfer to treat cancer patients.
   Google Scholar
• SCHULER M, ROCHLITZ C, HOROWITZ JA et al.: A Phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Human Gene Ther. (1998) 9:2075–2082.
   PubMed Web of Science ®Google Scholar
• ••Treatment of a larger number of lung cancer patients with awild-type p53 adenovirus. The study shows that the virus is well-tolerated and has antitumour effect in at least some patients.
   Google Scholar
• SWISHER SG, ROTH JA, NEMUNAITIS J et al: Adenoviral-mediated p53 gene transfer in advanced non-small cell lung cancer. J. Natl. Cancer Inst. (1999) (In Press).
   PubMedGoogle Scholar
• ••Another important study using adenovirus to deliverwild-type p53 to lung tumours.
   Google Scholar
• CLAYMAN GL, EL-NAGGAR AK, LIPPMAN SM et al.: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. (1998) 16:2221–2232.
   PubMed Web of Science ®Google Scholar
• ••Safe treatment of head and neck carcinomas with p53adenovirus.
   Google Scholar
• VOUSDEN KH: Interactions of human papilloma virustransforming proteins with the products of tumor suppressor genes. FASEB J. (1993) 7:872–879.
   PubMed Web of Science ®Google Scholar
• HAUPT Y, ROWAN S, OREN M: p53-mediated apoptosisin HeLa cells can be overcome by excess pRB. Oncogene (1995) 10:1563–1571.
   PubMed Web of Science ®Google Scholar
• SANDIG V, BRAND K, HERWIG S, LUKAS J, BARTEK J, STRAUSS M: Adenovirally transferred p16/INK4a and p53 genes co-operate to induce apoptotic tumor cell death. Nature Med. (1997) 3:313–319.
   PubMed Web of Science ®Google Scholar
• BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274:373–376.
   PubMed Web of Science ®Google Scholar
• ••The first description of an elegant strategy for specificelimination of tumour cells lacking wild-type p53 using an ElB 55K-deficient mutant adenovirus.
   Google Scholar
• HEISE C, SAMPSON-JOHANNES A, WILLIAMS A et al.: ONYX-015, an ElB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. (1997) 3:639–645.
   PubMed Web of Science ®Google Scholar
• •Further studies of the mutant adenovirus, including its antitumour properties.
   Google Scholar
• KIRN D, NEMUNAITIS J, GANLY I et al.: A Phase II trial with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:1509.
   Google Scholar
• ••Partly successful treatment of head and neck carcinomaswith the ElB 55K-deficient adenovirus.
   Google Scholar
• KIRN D, HERMISTON T, McCORMICK F: ONYX-015: clinical data are encouraging. Nature Med. (1998) 4:1341–1342.
   PubMed Web of Science ®Google Scholar
• HALL AR, DIX BR, O'CARROLL SJ, BRAITHVVAITE AW:p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med. (1998) 4:1068–1072.
   PubMed Web of Science ®Google Scholar
• •One of three recent studies that challenge the ONYX-015 strategy.
   Google Scholar
• ROTHMANN T, HENGSTERMANN A, WHITAKER NJ, SCHEFFNER M, ZUR HAUSEN H: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. (1998) 72:9470–9478.
   PubMed Web of Science ®Google Scholar
• •A demonstration that p53 status is not the only important determinant of ONYX-015 replication. Is ONYX-015 useless for cancer therapy?
   Google Scholar
• GOODRUM FD, ORNELLES DA: p53 status does not determine outcome of ElB 55-kilodalton mutant adenovirus lytic infection. J. Virol. (1998) 72:9479–9490.
   PubMed Web of Science ®Google Scholar
• •Another paper showing that ONYX-015 replication cannot be predicted only from p53 status of the infected cell.
   Google Scholar
• SELIVANOVA G, KAWASAKI T, RYABCHENKO L, WIMANKG: Reactivation of mutant p53: a new strategy for cancer therapy. Sem. Cancer Biol. (1998) 8:369–378.
   PubMedGoogle Scholar
• HUPP TR, MEEK DW, MIDGLEY CA, LANE DP: Activationof the cryptic DNA binding function of mutant forms of p53. Nucl. Acids Res. (1993) 21:3167–3174.
   PubMed Web of Science ®Google Scholar
• HALAZONETIS TD, KANDIL AN: Conformational shiftspropagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. (1993) 12:5057–5064.
   PubMedGoogle Scholar
• NIEWOLIK D, VOJTESEK B, KOVARIK J: p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene (1995) 10:881–890.
   PubMedGoogle Scholar
• ABARZUA P, LOSARDO JE, GUBLER ML, NERI A: Microin-jection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res. (1995) 55:3490–3494.
   PubMed Web of Science ®Google Scholar
• ABARZUA P, LOSARDO JE, GUBLER ML et al.: Restorationof the transcription activation function to mutant p53 in human cancer cells. Oncogene (1996) 13:2477–2482.
   PubMed Web of Science ®Google Scholar
• SELIVANOVA G, IOTSOVA V, OKAN I et al: Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med. (1997) 3:632–638.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration that a mutant p53-reactivatingpeptide can suppress growth and induce apoptosis in human tumour cells in a p53-dependent fashion.
   Google Scholar
• HUPP TR, MEEK DW, MIDGLEY CA, LANE DP: Regulation of the specific DNA binding function of p53. Cell (1992) 71:875–886.
   PubMed Web of Science ®Google Scholar
• •A milestone paper showing that the C-terminus of p53 is crucial for regulation of specific DNA binding by the p53 core domain.
   Google Scholar
• HALAZONETIS TD, DAVIS LJ, KANDIL AN: Wild-type p53adopts a 'mutant'-like conformation when bound to DNA. EMBO J (1993) 12:1021–1028.
   PubMed Web of Science ®Google Scholar
• HUPP TR, LANE DP: Allosteric activation of latent p53tetramers. Curr. Biol. (1994) 4:865–875.
   PubMedGoogle Scholar
• SELIVANOVA G, RYABCHENKO L, JANSSON E, IOTSOVAV, WIMAN KG: Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell. Biol. (1999) 19:3395–3402.
   PubMed Web of Science ®Google Scholar
• WIECZOREK AM, WATERMAN JL, WATERMAN MJ, HALAZONETIS TD: Structure-based rescue of common tumor-derived p53 mutants. Nature Med. (1996) 2:1143–1146.
   PubMedGoogle Scholar
• ••A study showing that certain common forms of mutant p53can be reactivated by second site mutations. This raises the possibility of designing drugs that bind specifically to mutant p53 and restore its wild-type activity.
   Google Scholar
• BRACHMANN RK, YU K, EBY Y, PAVLETICH NP, BOEKEJD: Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J (1998) 17:1847–1859.
   PubMedGoogle Scholar
• OLINER JD, KINZLER KW, MELTZER PS, GEORGE DL, VOGELSTEIN B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 358:80–83.
   PubMed Web of Science ®Google Scholar
• FLORENES VA, MAELANDSMO GM, FORUS A, ANDREASSEN A, MYKLEBOST O, FODSTAD 0: MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 status. J. Nati Cancer Inst. (1994) 86:1297–1302.
   PubMed Web of Science ®Google Scholar
• LANDERS JE, HAINES DS, STRAUSS JFR, GEORGE DL:Enhanced translation: a novel mechanism of MDM2 oncogene overexpression in human tumor cells. Oncogene (1994) 9:2745–2750.
   PubMed Web of Science ®Google Scholar
• CORDON-CARDO C, LATRES E, DROBNJAK M et al.: Molecular abnormalities of MDM2 and p53 genes in adult soft tissue sarcomas. Cancer Res. (1994) 54:794–799.
   PubMed Web of Science ®Google Scholar
• CAPOULADE C, BRESSAC-DE PAILLERETS B, LEFRERE I et al: Overexpression of MDM2, due to enhanced transla-tion, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene (1998) 16:1603–1610.
   PubMed Web of Science ®Google Scholar
• WU X, BAYLE H, OLSON D, LEVINE AJ: The p53-MDM2 autoregulatory loop. Genes Dev. (1993) 7:1126–1132.
   PubMed Web of Science ®Google Scholar
• HAUPT Y, MAYA R, KAZAZ A, OREN M: MDM2 promotes the rapid degradation of p53. Nature (1997) 387:296–299.
   PubMed Web of Science ®Google Scholar
• KUBBUTAT MHG, JONES SN, VOUSDEN KH: Regulation of p53 stability by MDM2. Nature (1997) 387:299–303.
   PubMed Web of Science ®Google Scholar
• BOTTGER A, BOTTGER V, SPARKS A, LIU WL, HOWARD SF, LANE DP: Design of a synthetic MDM2-binding mini-protein that activates the p53 response in vivo. Curr. Biol. (1997) 7:860–869.
   PubMed Web of Science ®Google Scholar
• ••This paper shows that the disruption of p53-MDM2 bindingby a mini-protein that binds tightly to MDM2 causes p53 accumulation and activation of p53-dependent cell cycle arrest. The results suggest the possibility of tumour therapy by pharmacological targeting of the p53-MDM2 interaction in wild-type p53-carrying tumours.
   Google Scholar